No connection

Search Results

CCEL vs KYNB

CCEL
Cryo-Cell International, Inc.
BEARISH
Price
$3.67
Market Cap
$29.6M
Sector
Healthcare
AI Confidence
95%
KYNB
Kyntra Bio, Inc.
BEARISH
Price
$7.17
Market Cap
$29.0M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
CCEL
--
KYNB
--
Forward P/E
CCEL
183.5
KYNB
-0.7
P/B Ratio
CCEL
-1.61
KYNB
-0.97
P/S Ratio
CCEL
0.95
KYNB
4.51
EV/EBITDA
CCEL
31.86
KYNB
0.13

Profitability

Gross Margin
CCEL
63.53%
KYNB
-273.8%
Operating Margin
CCEL
9.96%
KYNB
-1058.65%
Profit Margin
CCEL
-8.52%
KYNB
2848.63%
ROE
CCEL
--
KYNB
--
ROA
CCEL
0.19%
KYNB
-16.96%

Growth

Revenue Growth
CCEL
-3.6%
KYNB
-59.3%
Earnings Growth
CCEL
-80.5%
KYNB
--

Financial Health

Debt/Equity
CCEL
--
KYNB
4.37
Current Ratio
CCEL
0.62
KYNB
3.39
Quick Ratio
CCEL
0.55
KYNB
3.19

Dividends

Dividend Yield
CCEL
16.35%
KYNB
--
Payout Ratio
CCEL
3962.91%
KYNB
0.0%

AI Verdict

CCEL BEARISH

CCEL exhibits severe financial distress, highlighted by a weak Piotroski F-Score of 2/9 and a negative Price/Book ratio of -1.61, suggesting negative shareholder equity. The company's dividend is fundamentally unsustainable with a payout ratio of 3962.91%, indicating that dividends are being paid out of capital or debt rather than earnings. While gross margins remain strong, the combination of declining YoY revenue (-3.60%) and crashing earnings growth (-80.50%) creates a precarious outlook. Liquidity is a critical concern with a current ratio of 0.62, placing the firm at significant short-term financial risk.

Strengths
Strong gross margins at 63.53%
Positive operating margin of 9.96%
Low Price/Sales ratio of 0.95
Risks
Negative equity as indicated by Price/Book ratio of -1.61
Severe liquidity risk with a current ratio of 0.62 and quick ratio of 0.55
Unsustainable dividend payout ratio (3962.91%)
KYNB BEARISH

KYNB exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a negative Price-to-Book ratio (-0.97), indicating that liabilities exceed assets. While the company maintains a healthy current ratio (3.39), the underlying fundamentals are deteriorating with a YoY revenue decline of 59.30% and a catastrophic 5-year price depreciation of 98.6%. The reported profit margin is a mathematical anomaly likely driven by a one-time non-operating gain, as the operating margin remains deeply negative at -1058.65%. Despite a lone analyst's aggressive price target of $43.00, the deterministic data suggests a high risk of insolvency or further dilution.

Strengths
Strong short-term liquidity (Current Ratio 3.39)
Quick ratio (3.19) suggests sufficient liquid assets for immediate obligations
Recent 1-year price performance is slightly positive (+10.3%)
Risks
Negative equity (Price/Book -0.97) indicating technical insolvency
Severe revenue contraction (-59.30% YoY)
Extremely poor financial health (Piotroski F-Score 1/9)

Compare Another Pair

CCEL vs KYNB: Head-to-Head Comparison

This page compares Cryo-Cell International, Inc. (CCEL) and Kyntra Bio, Inc. (KYNB) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile